Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1655501 | 0.83 | NISCH (0.42) | ADRA1DADRA1AADRA1BNISCHHTR1D | |
| SCHEMBL29618250 | 0.83 | NISCH (0.42) | ADRA1DADRA1AADRA1BNISCHHTR1D | |
| SCHEMBL27908754 | 0.81 | HTR1D (0.43) | ADRA1DADRA1AADRA1BNISCHHTR1D | |
| SCHEMBL30512039 | 0.80 | LMNA (0.47) | LMNAHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL17727605 | 0.76 | CYP2D6 (0.48) | HTTSMN1; SMN2ALDH1A1POLBMAPT | |
| SCHEMBL25427630 | 0.75 | HTT (0.43) | LMNAHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL9348425 | 0.74 | SMN1; SMN2 (0.57) | LMNAHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1656075 | 0.73 | SMN1; SMN2 (0.53) | LMNAHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL18949407 | 0.73 | HTT (0.58) | LMNAHTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1655496 | 0.72 | LMNA (0.50) | LMNAHTTSMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107278204-B | Synthesis of Copanlisib and its dihydrochloride | 拜耳制药股份公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3215493-B1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3215493-B1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-20180282337-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | US | disclosed |
| EP-3215493-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016071435-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071435-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071382-A1 | SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071382-A1 | SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071380-A1 | SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071380-A1 | SYNTHESIS OF PI3K INHIBITOR AND SALTS THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| EP-3018127-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018127-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282337-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | COPS2, COPS4, COPS6 | LMNA 3771/4885HTT 270/4885SMN1; SMN2 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.